S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Biden's Plan to Confiscate Your Cash? (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Biden's Plan to Confiscate Your Cash? (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Biden's Plan to Confiscate Your Cash? (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Biden's Plan to Confiscate Your Cash? (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
NASDAQ:CLDX

Celldex Therapeutics - CLDX Stock Forecast, Price & News

$37.33
+2.80 (+8.11%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$34.31
$37.98
50-Day Range
$20.50
$37.47
52-Week Range
$19.85
$57.20
Volume
582,593 shs
Average Volume
563,335 shs
Market Capitalization
$1.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$67.67

Celldex Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
81.3% Upside
$67.67 Price Target
Short Interest
Bearish
30.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Celldex Therapeutics in the last 14 days
Based on 31 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.30) to ($2.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

923rd out of 1,135 stocks

Diagnostic Substances Industry

13th out of 17 stocks

CLDX stock logo

About Celldex Therapeutics (NASDAQ:CLDX) Stock

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Celldex Therapeutics Price Performance

Shares of CLDX Stock traded up $2.80 during trading hours on Friday, hitting $37.33. 582,593 shares of the company's stock were exchanged, compared to its average volume of 563,335. Celldex Therapeutics has a 52 week low of $19.85 and a 52 week high of $57.20. The stock's 50-day moving average is $27.91 and its 200-day moving average is $30.11.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. SVB Leerink cut their price objective on Celldex Therapeutics from $68.00 to $64.00 and set an "outperform" rating for the company in a report on Tuesday. HC Wainwright boosted their price target on shares of Celldex Therapeutics from $60.00 to $73.00 and gave the company a "buy" rating in a research report on Friday, July 1st.

Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CLDX Stock News Headlines

See More Headlines
Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CLDX Company Calendar

Last Earnings
11/09/2021
Today
8/13/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CLDX
CUSIP
15117B10
Employees
132
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$67.67
High Stock Price Forecast
$73.00
Low Stock Price Forecast
$64.00
Forecasted Upside/Downside
+81.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-70,510,000.00
Net Margins
-12,108.63%
Pretax Margin
-12,136.21%

Debt

Sales & Book Value

Annual Sales
$4.65 million
Book Value
$7.81 per share

Miscellaneous

Free Float
45,649,000
Market Cap
$1.75 billion
Optionable
Optionable
Beta
2.43

Social Links


Key Executives














CLDX Stock - Frequently Asked Questions

Should I buy or sell Celldex Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLDX shares.
View CLDX analyst ratings
or view top-rated stocks.

What is Celldex Therapeutics' stock price forecast for 2022?

4 brokers have issued 12-month target prices for Celldex Therapeutics' stock. Their CLDX share price forecasts range from $64.00 to $73.00. On average, they anticipate the company's share price to reach $67.67 in the next year. This suggests a possible upside of 81.3% from the stock's current price.
View analysts price targets for CLDX
or view top-rated stocks among Wall Street analysts.

How have CLDX shares performed in 2022?

Celldex Therapeutics' stock was trading at $38.64 at the start of the year. Since then, CLDX stock has decreased by 3.4% and is now trading at $37.33.
View the best growth stocks for 2022 here
.

When is Celldex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CLDX earnings forecast
.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.09. The biopharmaceutical company earned $0.15 million during the quarter, compared to analysts' expectations of $1.70 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 21.79% and a negative net margin of 12,108.63%.

When did Celldex Therapeutics' stock split?

Celldex Therapeutics's stock reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.99%), Ikarian Capital LLC (0.00%), Northern Trust Corp (0.91%), Candriam S.C.A. (0.62%), TSP Capital Management Group LLC (0.57%) and Deutsche Bank AG (0.36%). Insiders that own company stock include Anthony S Marucci, Diane C Young, Elizabeth Crowley, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, Sarah Cavanaugh and Tibor Keler.
View institutional ownership trends
.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $37.33.

How much money does Celldex Therapeutics make?

Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.75 billion and generates $4.65 million in revenue each year. The biopharmaceutical company earns $-70,510,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis.

How many employees does Celldex Therapeutics have?

The company employs 132 workers across the globe.

When was Celldex Therapeutics founded?

Celldex Therapeutics was founded in 1983.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for the company is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 200-7500, via email at ir@celldextherapeutics.com, or via fax at 908-454-1911.

This page (NASDAQ:CLDX) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.